Naltrexone linked to reduction in pain in fibromyalgia

February 12, 2013
Naltrexone linked to reduction in pain in fibromyalgia
Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.

(HealthDay)—Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.

Jarred Younger, Ph.D., from the Stanford University School of Medicine in Palo Alto, Calif., and colleagues conducted a crossover study involving 31 women with who were randomly assigned to a four-week placebo stage and a 12-week active phase comprising 4.5 mg/day of naltrexone. Daily levels of pain were assessed.

The researchers found that baseline pain was significantly reduced in patients taking low-dose naltrexone versus placebo (reduction of 28.8 percent versus 18.0 percent). There was also significant improvement in general satisfaction with life and mood in patients taking naltrexone, although there was no improvement in fatigue or sleep. The response rate, as assessed by significant reductions in pain plus a significant reduction either fatigue or sleep problems, was significantly higher for low-dose naltrexone than placebo (32 versus 11 percent). Naltrexone was as well tolerated as placebo and there were no serious side effects.

"Our replicated observation that low-dose naltrexone affects levels of , together with the low cost and tolerable nature of low-dose , makes it a promising target for future investigation," Younger and colleagues conclude.

Explore further: Use of naltrexone reduces inflammation in Crohn's patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Asians fighting alcoholism may benefit from new study

September 27, 2011

(Medical Xpress) -- New UCLA psychology research indicates that Asians who are struggling with alcoholism may benefit especially from naltrexone, one of three medications approved by the U.S. Food and Drug Administration ...

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Study sheds light on pain pill abuse

September 26, 2012

A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse. The ...

Recommended for you

Molecular Zika study finds possible target for tests, drugs

April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a ...

Zika virus may now be tied to another brain disease

April 10, 2016

The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.